Axil Capital Fund I | 2026 VC Fund

Axil Capital

cb Email

Status

ACTIVE

Global HQ

Tokyo, Japan

Countries of investment

Japan
United States

Investment stages

Seed
Series A

Industries

Biomedical
Healthcare
Life Sciences
Medical Technology
Therapeutics
Drug Discovery
Medical Devices

About
Axil Capital is a Tokyo-based venture capital firm focused on backing early-stage biomedical and healthcare technology ventures. Their focus spans biomedical, healthcare, life sciences, and medical technology across Japan and the United States. The firm supports healthcare founders from seed through Series A stages.

Min check size: $500K
Max check size: $3M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Axil Capital is a seed and Series A stage venture capital firm deploying capital across biomedical, healthcare, life sciences, and medical technology sectors. They invest in early-stage ventures with strong scientific and technological foundations, providing financial resources and strategic guidance. The firm differentiates itself as a Tokyo-based biomedical specialist providing capital and strategic guidance to healthcare innovators across Japan and international markets.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2017. Small team of 2 members including current Managing Partner Fred Shane. Based in Tokyo at 1-11-4 Nishi-Shinbashi, 7th Floor Nitto Nishi-Shinbashi Building. Focused on early-stage biomedical and healthcare technology investments. Notable portfolio includes PUL-042 R&D (supported by Department of Defense, NIH NIAID/NIGMS, CPRIT). Partners with Fannin Innovation Studio (Houston-based) for portfolio company development. Leverages Japanese healthcare ecosystem connections while investing in innovative biomedical ventures globally.